Cardioprotective effects of curcumin

Advances in Experimental Medicine and Biology

Volumn 595, Issue , 2007, Pages 359-377

  Miriyala, Sumitra ^a   Panchatcharam, Manikandan ^a   Rengarajulu, Puvanakrishnan ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b CENTRAL LEATHER RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CURCUMA LONGA EXTRACT; CURCUMIN; GLUTATHIONE TRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; IBUPROFEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXYGEN RADICAL; PHENYLBUTAZONE;

ANTICOAGULATION; ANTIOXIDANT ACTIVITY; ARACHIDONIC ACID METABOLISM; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CONSTIPATION; DIARRHEA; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINAL BLEEDING; LEUKOCYTE COUNT; LIPID PEROXIDATION; LOW DRUG DOSE; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTE AGGREGATION; ULCER;

CURCUMA LONGA; RATTUS; ZINGIBERACEAE;

EID: 84934437386     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-46401-5_16     Document Type: Review

References (108)

1. H. P. T. Ammon and M. A. Wahl, Pharmacology of Curcuma longa. Planta Med 57, 1-7 (1991).
2. R. C. Srimal, Turmeric. A brief review of medicinal properties. Fitoterapia. 68, 483-493 1997).
3. S. Toda, Antioxidative components isolated from rhizome of Curcuma longa L. Chem Pharm Bull33, 1725-1728 (1985).
4. Y. Abe, S. Hashimoto, and T. Horie, Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 39, 41-47 (1999).
5. J. L. Quiles, M. D. Mesa, C. L. Ramirez-Tortosa , C. M. Aguilera , M. Battino, A. Gil, M. C. Ramirez-Tortosa, Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty streak development in rabbits. Arterioscler Thromb Vasc Biol 22,1225-1231 (2002).
6. L. Pilgeram, Atherogenesis and fibrinogen: Historical perspective and current status. Naturwissenschaften 80, 547-555 (1993).
7. K. Von Rokitansky, Handbuch der Pathologischen Anatomie, Vols. 1-3. Vienna: Braunmuller und Seidel, 1846.
8. C. Anitschow, In: E. V. Cowdry, ed. Arteriosclerosis: A Survey of the Problem. New York: McMillan, New York, 1933, pp.107-121.
9. R. O. Hynes, Integrins: A family of cell surface receptors. Cell 48, 549-554 (1987).
10. S. S. Smyth, C. C. Joneckis, and L. V. Parise, Regulation of vascular integrins. Blood 81, 2827-2843 (1993).
11. W. H. Frishman, B. Burns, B. Atac, N. Alturk B. Altajar, and K. Lerrick, Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 130, 877-892 (1995).
12. K. C. Srivastava and T. Mustafa, Spices: Antiplatelet activity and prostanoid metabolism. Prostaglandins Leukotr Essent Fatty Acids 8, 255-266 (1989).
13. K. C. Srivastava and O. D. Tyagi, Effects of a garlic-derived principle (ajoene) on aggregation and arachidonic acid metabolism in human blood platelets. Prostaglandins Leukotr Essent Fatty Acids 49, 587-595 (1993).
14. K. C. Srivastava, Extracts of two frequently consumed spices - cumin (Cuminum cyminum) and turmeric (Curcuma longa) - inhibit aggregation and alter eicosanoid biosynthesis in human blood platelets. Prostaglandins Leukotr Essent Fatty Acids 37, 57-64 (1989).
15. K. C. Srivastava, A. Bordia, and S. K. Verma, Curcumin, a major component of food spice turmeric (Curcuma longa), inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukotr Essent Fatty Acids 52, 223-227 (1995).
16. J. Lefkovits, E. F. Plow, and E. J. Topol, Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 332, 1553-1559 (1995).
17. M. T. Huang, T. Lysz, T. Ferraro, T. F. Abidi, J. D Laskin, and A. H. Conney, Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities ischemia in rats. Int J Biochem Cell Biol 36, 1967-1980 (1991).
18. P. Manikandan, M. Sumitra, S. Aishwarya, B. M. Manohar, B. Lokanadam, and R. Puvanakrishnan, Curcumin modulates free radical quenching in myocardial in mouse epidermis. Cancer Res 51, 813-819 (2004).
19. S. Offermans , Kl. Laugwitz, K. Spicher, and G. Schultz, G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci USA 91, 504-508 (1994).
20. S. D. Shukla, C. C. Franklin, and M. G. Carter, Activation of phospholipase C in platelets by platelet activating factor and thrombin causes hydrolysis of a common pool of phosphatidylinositol 4,5- bisphosphate. Biochim Biophys Acta 929, 134-141 (1987).
21. M. R. James-Kracke, R. B. Sexe, and S. D. Shukla, Picomolar platelet activating factor mobilizes Ca21 to change platelet shape without activating phospholipase C or protein kinase C; simultaneous measurements of intracellular free Ca21 concentration and aggregation. J Pharmacol Exp Ther 271, 824-831 (1994).
22. W. Siess, Molecular mechanisms of platelet activation. Physiol Rev 69, 58-178 (1989).
23. J. W. M. Heemskerk and O. Sage, Calcium signaling in platelets and other cells. Platelets 5, 295-316 (1994).
24. D. E. Clapham, Calcium signaling. Cell 80, 259-268 (1995).
25. M. Crabos, D. Fabbro, S. Stabel, and P. Erne, Effect of tumor promoting phorbol ester, thrombin platelets and regulation by calcium. Biochem J 288, 891-896 (1992).
26. A. C. Newton, Protein kinase C: Structure, function and regulation. J Biol Chem 270, 28,495-28,498 (1995).
27. T. M. Quinton and W. L. Dean, Multiple inositol 1,4,5-triphosphate receptor isoforms are present in platelets. Biochem Biophys Res Commun 224, 740-746 (1996).
28. L. F. Brass, J. A. Hoxie, and D. R. Manning, Signaling through G proteins and G protein-coupled receptors during platelet activation. Thromb Haemost 70, 217-223 (1993).
29. W. Siess, B. Grunberg, and K. Luber, Functional relationship between cyclic AMP dependent protein phosphorylation and platelet inhibition. Adv Exp Med Biol 344, 229-235 (1993).
30. S. M. O. Hourani and D. A. Hall, Receptors for ADP on human blood platelets. Trends Pharmacol Sci 15, 103-108 (1994).
31. W. Chao and M. S. Olson, Platelet-activating factor: Receptors and signal transduction. Biochem J 292, 617-629 (1993).
32. S. A. Saeed and B. H. Shah, Diversity of agonist-mediated signal transduction pathways in human platelets. Adv Exp Med Biol 407, 531-535 (1997).
33. B. H. Shah , D. J. McEwan, and G. Milligan, Gonadotrophin releasing hormone receptor agonist-mediated down-regulation of Gqa/G11 a (pertussis toxin-insensitive) G proteins in aT3-1 gonadotroph cells reflects increased G protein turnover but not alterations in mRNA levels. Proc Natl Acad Sci USA 92, 1886-1889 (1995).
34. J. Kawabe, G. Iwami, T. Ebina, S. Ohno, T. Katada, Y. Ueda, C. J. Homcy, and Y. Ishikawa, Differential activation of adenylyl cyclase by protein kinase C isoenzymes. J Biol Chem 269, 16,554-16,558 (1994).
35. J. Y. Liu, S. J. Lin, and J. K. Lin, JInhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoylphorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 14, 857-861 (1993).
36. J. K. Lin, Y. C. Chen, Y. T. Huang, and S. Y. Lin-Shiau, Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. J Cell Biochem Suppl 28-29, 39-48 (1997).
37. X. Wang, S. Yanagi, C. Yang, R. Inatome, and H. Yamamura, Tyrosine phosphorylation and SYK activation are involved in thrombin-induced aggregation of epinephrine-potentiated platelets. J Biochem 121, 325-330 (1997).
38. Y. Banno, T. Asano, and Y. Nozawa, Stimulation by G protein bg subunits of phospholipase Cb isoforms in human platelets.Thromb Haemost 79, 1008-1013 (1998).
39. K. L. Kaplan. and A. Bini, Thrombosis in atherogenesis. Crit Rev Oncol Hematol 9, 305-318 (1989).
40. E. B. Smith, R. S. Slater, and J. A. Hunter, Quantitative studies on fibrinogen and low-density lipoprotein in human aortic intima. Atherosclerosis 55, 171-178 (1973).
41. E. Ernst and K. L. ReschFibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 118, 956-963 (1993).
42. A. Ramý'rez-Bosca', M. A Carrio'n Gutie'rrez, A. Soler, et al., Effects of the antioxidant turmeric on lipoprotein peroxides: Implications for the prevention of atherosclerosis. Age 20,165-168 (1997).
43. A. Ramý'rez-Bosca', A. Soler, M. A. Carrio'n-Gutie'rrez, A. Laborda Alvarez, and E. Quintanilla Almagro, Antioxidant curcuma extracts decrease the blood lipid peroxide levels of human subjects. Age 18, 167-169 (1995).
44. A. Claus, Fibrinogens. Acta Haemat 7, 237 (1957).
45. T. Masuda, J. Isobe, A. Jitoe, and N. Nakatani, Antioxidative curcuminoids from rhizomes of Curcumaxantorrhyza. Phytochemistry 31, 3645-3647 (1992).
46. T. N. Bhavani Shankar, N. V. Shantha, H. P. Ramesh, I. A. S. Murthy, and V. S. Murthy, Toxicity studies on turmeric (Curcuma longa): Acute toxicity studies in rats, guinea pigs and monkeys. Ind J Exp Biol 18, 73-75 (1980).
47. G. K. Hansson, Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352, 1685-1695 (2005).
48. A. Doria, Y. Sherer, P. L. Meroni and Y. Shoenfeld, Inflammation and accelerated atherosclerosis: Basic mechanisms. Rheum Dis Clin North Am 31, 355-362 (2005).
49. J. Miquel, M. Martínez, A. Diez, E. De Juan, A. Solar, A. Ramírez-Boscá, J. Laborda, and M. Carriona, Effects of turmeric on blood and liver lipoperoxide levels of mice: Lack of toxicity. Age 18, 171-174 (1995).
50. M. C. Ramírez-Tortosa , M. D. Mesa, M. C. Aguilera, J. L. Quiles, L. Baró, C. L. Ramírez-Tortosa, E. Martínez-Victoria, and A. Gil, Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effect in rabbits with experimental atherosclerosis. Atherosclerosis 147, 371-378 (1999).
51. H. W. Chen and H. C. Huang, Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br J Pharmacol 124, 1029-1040 (1998).
52. K. C. Srivastava, Evidence for the mechanism by which garlic inhibits platelet aggregation. Prostaglandins Leukotr Med 22, 313-321 (1986).
53. C. C. Araujo, and L. L. Leon,.Biological activities of Curcuma longa L. Mem Inst Oswaldo Cruz 96,723-728 (2001).
54. B. B. Aggarwal, A. Kumar, and A. C. Bharti, Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 23, 363-398 (2003).
55. A. Duvoix, R. Blasius, S. Delhalle, M. Schnekenburger , F. Morceau, E. Henry, et al., Chemopreventive and therapeutic effects of curcumin. Cancer Lett 223, 181-190 (2005).
56. J. A. Piedrahita, S. H. Zhang, J. R. Hagaman, P. M. Oliver, and N. Maeda, Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 89, 4471-4475 (1992).
57. S. Ishibashi , J. Herz, N. Maeda, J. L. Goldstein, and M. S. Brown, The two-receptor model of lipoprotein clearance: Tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci USA 91, 4431-4435 (1994).
58. Y. Nakashima, A. S. Plump, E. W. Raines, J. L. Breslow, and R. Ross, ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14, 133-140 (1994).
59. G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran, and P. S. Srinivas, Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64, 353-356 (1998).
60. C. Monaco and E. Paleolog, Nuclear factor kappaB: A potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 61, 671-682 (2004).
61. J. Jawien, M. Gajda, L. Mateuszuk, R. Olszanecki, A. Jakubowski, A Szlachcic, et al., Inhibition of nuclear factor-kappaB attenuates artherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 56, 483-489 (2005).
62. K. Hishikawa, T. Nakaki, and T. Fujita, Oral flavonoid supplementation attenuates atherosclerosis development in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 25, 442-446 (2005).
63. B. Gupta and B. Ghosh, Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells. Int J Immunopharmacol 21, 745-757 (1999).
64. K. A. Hoekstra, D. V. Godin, and K. M. Cheng, Protective role of heme oxygenase in the blood vessel wall during atherogenesis. Biochem Cell Biol 82, 351-359 (2004).
65. N. G. Abraham and A. Kappas, Heme oxygenase and the cardiovascular-renal system. Free Radical Biol Med 39, 1-25 (2005).
66. S. H. Juan, T. S. Lee, K. W. Tseng, J. Y. Liou, S. K. Shyue, , K. K. Wu, et al., Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E deficient mice.Circulation. 104, 1519-1525 (2001).
67. S. F. Yet, M. D. Layne X. Liu, Y. H. Chen, B. Ith, N. E. Sibinga, et al., Absence of heme oxygenase-1e xacerbates atherosclerotic lesion formation and vascular remodeling. FASEB J 17, 1759-1761 (2003).
68. R. Motterlini, R. Foresti, R. Bassi, and C. J. Green, Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radical Biol Med 28, 1303-1312 (2000).
69. E. Middleton, Jr., C. Kandaswami, T. C. Theoharides, The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol Rev 52, 673-751 (2000).
70. S. Schmitt-Schillig , S. Schaffer, C. C. Weber , G. P. Eckert , and W. E. Muller, Flavonoids and the aging brain. J Physiol Pharmacol 56(Suppl 1), 23-36 (2005).
71. O. S. Zayachkivska, S. J. Konturek, D. Drozdowicz, P. C. Konturek , T. Brzozowski, and M. R. Ghegotsky, Gastroprotective effects of flavonoids in plant extracts. J Physiol Pharmacol 56, 219-231 (2005).
72. C. Manach, A. Mazur, and A. Scalbert, Polyphenols and prevention of cardiovascular diseases. Curr Opin Lipidol 16, 77-84 (2005).
73. M. Aviram and B. Fuhrman, wine flavonoids protect against LDL oxidation and atherosclerosis. Ann NY Acad Sci 957, 146-161 (2002).
74. R. Olszanecki, A. Gebska, V. I. Kozlovski, and R. J. Gryglewski, Flavonoids and nitric oxide synthase. J Physiol Pharmacol 53, 571-584 (2002).
75. S. J. Duffy and J. A. Vita, Effects of phenolics on vascular endothelial function. Curr Opin Lipidol 14, 21-27 (2003).
76. M. Strzelecka, M. Bzowska, J. Koziel, B. Szuba, O. Dubiel, N. D. Riviera, et al., Anti-inflammatory effects of extracts from some traditional Mediterranean diet plants. J Physiol Pharmacol 56, 139-156 (2005).
77. J. C. Ruf, Wine and polyphenols related to platelet aggregation and atherothrombosis. Drugs Exp Clin Res 25, 125-131 (1999).
78. N. Venkatesan, Pulmonary protective effects of curcumin against paraquat toxicity. Life Sci 66, 21-28 (2000).
79. S. Toda,, T. Miyase, H. Arichi, H. Tanizawa, and Y. Takino, Natural antioxidants. III. Antioxidative components isolated from rhizome of Curcuma longa L. Chem Pharma Bull 33, 1725-1728 (1985).
80. A. C. Reddy and B. R. Lokesh, Studies on the inhibitory effects of curcumin and eugenol on the formation of reactive oxygen species and the oxidation of ferrous iron. Mol Cell Biochem 137, 1- 8 (1994).
81. M. K. Unnikrishnan and M. N. Rao, Curcumin inhibits nitrogen dioxide induced oxidation of hemoglobin. Mol Cell Biochem 146, 35-37 (1995).
82. N. Sreejayan and M. N. A. Rao, Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol. 49, 105-107 (1997).
83. A. C. Reddyand B. R. Lokesh, Studies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomes. Mol Cell Biochem 111 , 117-124 (1992).
84. N. Sreejayan and M. N. A. Rao, Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 46, 1013-1016 (1994).
85. 2-induced renal epithelial (LLCPK1) cell injury. Free Radical Biol Med 24, 49-54 (1998).
86. M. Dikshit, L. Rastogi, R. Shukla, and R. C. Srimal,. Prevention of ischemia-induced biochemical changes by curcumin and quinidine in the cat heart. Ind J Med Res 101, 31-35 (1995).
87. C. Nirmala and R. Puvanakrishnan, Effect of curcumin on certain lysosomal hydrolases in isoproterenol-induced myocardial infarction in rats. Biochem Pharmacol 51, 47-51 (1996).
88. C. Nirmala and R. Puvanakrishnan, Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mol Cell Biochem 159, 85-93 (1996).
89. C. Nirmala, S. Anand, and R. Puvanakrishnan, Curcumin treatment modulates collagen metabolism in isoproterenol induced myocardial necrosis in rats. Mol Cell Biochem 197, 31-37 (1999).
90. J. P. Gaddipati, S. V. Sundar, J. Calemine, P. Seth, G. S. Sidhu, and R. K. Maheshwari, Differential regulation of cytokines and transcription factors in liver by curcumin following hemorrhage/resuscitation. Shock 19, 150-156 (2003).
91. P. Rafiee, Y. Shi, K. A. Pritchard, H. Ogawa, A. L. Eis, R. A. Komorowski, C. M. Fitzpatrick, J. S. Tweddell, S. B. Litwin, K. Mussatto, R. D. Jaquiss, and J. E. Baker, Cellular redistribution of inducible Hsp70 protein in the human and rabbit heart in response to the stress of chronic hypoxia: Role of protein kinases. J Biol Chem 278, 43,636-43,644 (2003).
92. P. Rafiee, Y. Shi, X., Kong, K. A. Pritchard, Jr., J. S. Tweddell, S. B. Litwin, K. Mussatto, R. D. Jaquiss, J. Su, and J. E. Baker, Activation of protein kinases in chronically hypoxic infant human and rabbit hearts: Role in cardioprotection. Circulation 106, 239-245 (2002).
93. N. Sreejayan and M. N. A. Rao, Free radical scavenging activity of curcuminoids. Arzneimittelforschung 6, 169-171 (1996).
94. C. V. Rao, A. Rivenson , B. Simi, and B. S. Reddy, Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55, 259-266 (1995).
95. A. J. Ruby, G. Kuttan, K. D. Babu, K. N. Rajasekharan, and R. Kuttan, Anti-tumor and antioxidant activity of natural curcuminoids. Cancer Lett 94, 79-83 (1995).
96. J. M. McCord, Oxygen-derived free radicals in post-ischaemic tissue injury. N Eng J Med 312, 159-163 (1985).
97. Y. Xia and J. L. Zweier, Substrate control of free radical generation from xanthine oxidase in the post-ischaemic heart. J Biol Chem 270, 18,797-18,803 (1995).
98. W. F. Saavedra, N. Paolocci, M. E. St John, M. W. Skaf, G. C. Stewart, J. S. Xie, et al., Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 90, 297-304 (2002).
99. L. S. Terada, D. M. Guidot, J. A. Leff, I. R. Willingham, M. E. Hanley, D. Piermattei, and J. E. Repine, Hypoxia injures endothelial cells by increasing endogenous xanthine oxidase activity. Proc Natl Acad Sci USA 89, 3362-3366 (1992).
100. E. Kunchandy and M. N. A. Rao, Oxygen radical scavenging activity of curcumin. Int J Pharm 58, 237-240 (1990).
101. T. Matsuyama, Free radical-mediated cerebral damage after hypoxia/ischemia and stroke. In: G. J. Ter Horst and J. Korf, eds. Clinical Pharmacology of Cerebral Ischemia. Totowa, NJ: Humana Press, 1997. pp. 153-184.
102. M. Pan, T. Huang, and J. Lin, Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27, 486-494 (1999).
103. J. A. Thomas, Oxidative stress, oxidant defense, and dietary constituents. In Modern Nutrition in Health and Disease, 8th ed. Lea & Febiger, Phil.; 1994, pp. 501-512.
104. M. Seif-El-Nasr and A. A. Abd-El-Fattah, Lipid peroxide, phospholipids, glutathione levels and superoxide dismutase activity in rat brain after ischemia: Effect of Ginkgo biloba extract. Pharmacol Res 32, 273-278 (1995).
105. S. Mathews and M. N. A. Rao, Interaction of curcumin with glutathione. Int J Pharm 76, 257-259 (1991).
106. S. V. Jovanovic, C. W. Boone, S. Steenken, M. Trinoga, and R. B. Kaskey, How curcumin works preferentially with water-soluble antioxidants. J Am Chem Soc 123, 3064-3068 (2001).
107. R. K. Maheshwari, A. K. Singh, J. Gaddipati, and R. C. Srimal, Multiple biological activities of curcumin: A short review. Life Sci 78, 2081-2087 (2006).
108. K. I. Priyadarsini, Free radical reactions of curcumin in membrane models. Free Radical Biol Med 23, 838-843 (1997).